PDF(Sci-hub)
Abstract：
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in 22 provinces of China. Fifty-four patients (7.3%) received monotherapy, 264 (36.0%) received chemoimmunotherapy, 395 (53.8%) received other combination regimens without rituximab, and 21 (2.9%) received ibrutinib. Using a multivariable Cox regression model, age > 65 years old, platelets <100 × 109/L, serum albumin <3.5 g/dl, β2 microglobulin concentration ≥4 mg/L and LDH ≥250 IU/L predicted poor OS. In summary, our study showed that frontline treatment choices for WM are widely heterogeneous. We validated most of the established prognostic factors in the rIPSS (age >65 years, LDH ≥250 IU/L, ALB <3.5 g/dl and β2 microglobulin ≥4 mg/L) together with PLT ≤ 100 × 109/L indicate a poor prognosis for patients with WM.
摘要：
在这项研究中,我们旨在探讨中国WM患者的治疗方案和预后.这项回顾性研究包括2003年1月至2019年12月在中国22个省的35家三级医院诊断为有症状WM的1141例患者。54例患者(7.3%)接受单一疗法,264人（36.0％）接受了化学免疫疗法，395（53.8％）接受了其他不使用利妥昔单抗的联合治疗方案，21人(2.9%)接受伊布替尼治疗.使用多变量Cox回归模型，年龄>65岁，血小板<100×109/L，血清白蛋白<3.5g/dl，β2微球蛋白浓度≥4mg/L和LDH≥250IU/L可预测OS差。总之,我们的研究表明，WM的一线治疗选择广泛异质。我们验证了rIPSS中大多数已确定的预后因素(年龄>65岁，LDH≥250IU/L，ALB<3.5g/dl和β2微球蛋白≥4mg/L）与PLT≤100×109/L表明WM患者的预后不良。
